CD4 and adenocarcinoma: Among CD3+ T cells, CD4+ T cells were the most frequent (28.6% in adenocarcinoma and 22.1% in squamous cell carcinoma, Figure 3B) followed by CD8+ T cells (23.9% in adenocarcinoma and 18.2% in squamous cell carcinoma, Figure 3C).